

**Remarks**

Applicants respectfully point out that the present application is a File Wrapper Continuation of U.S. Application Serial No. 07/915,884, filed July 20, 1991, which is a File Wrapper Continuation of U.S. Application Serial No. 07/308,282 filed February 9, 1989. According to the MPEP 6<sup>th</sup> Edition, Revision 2, Section 2421.01, “[f]or the purposes of the sequence rules, the term “new” with regard to applications means: -For regular US applications, the application must have been filed on or after October 1, 1990. Continuing applications that claim a date prior to October 1, 1990, under 35 U.S.C. 120, except continuations-in-part (CIPs) filed on or after October 1, 1990, where material added includes a sequence, are not new applications.” Similarly, the Final Rule for Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures published in the Official Gazette at 1121 O.G. 82 (June 23, 1998) states that “[s]ections 1.821 through 1.825 as amended apply to applications filed on or after July 1, 1998, except for: (1) applications that claim the benefit of a prior application under 35 U.S.C. 120 filed before July 1, 1998, and which do not add subject matter involving a sequence listing subject to 1.821 through 1.825...” Therefore, since the present application is a continuation that claims priority under 35 U.S.C. § 120 to an application filed prior to October 1, 1990 and does not add any matter, this application is not subject to the sequence rules set forth in sections 37 C.F.R. § 1.821 through 37 C.F.R. §1.825.

Although the present application is not subject to the sequence rules and applicants are not required to provide a Sequence Listing, applicants voluntarily enclose herewith a diskette containing a Sequence Listing for this application in computer readable form (CRF) and a paper copy of the Sequence Listing in compliance with 37 C.F.R. § 1.821-1.825. Applicants hereby


certify that the information in the computer readable form on the diskette and in the hard copy of the Sequence Listing is the same and includes no new matter.

The description of Figure 3 is amended herein on page 15 to refer to the amino acid sequence and the nucleotide sequence set forth in Figure 3 as SEQ ID NO: 1 and SEQ ID NO: 2, respectively. The description of Figure 3 on page 76 is similarly amended. No new matter is added by these amendments.

A Credit Card Payment Form PTO-2038 authorizing payment in the amount of \$120.00, representing the fee for a large entity under 37 C.F.R. § 117(a)(1) and a Request for Extension of Time and a Sequence Listing are enclosed. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.



Lizette M. Fernandez, Ph.D.  
Patent Agent  
Registration No. 46,694

NEEDLE & ROSENBERG, P.C.


Customer Number 36339

(678) 420-9300 Phone

(678) 420-9301 Fax

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

  
Lizette M. Fernandez, Ph.D.

Date

3/6/06